# Hans Van Vlierberghe

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/hans-van-vlierberghe/

## Facts

| Field | Value |
| --- | --- |
| Citations | 23,995 |
| Field | Liver Disease Diagnosis and Treatment |
| h-index | 66 |
| i10-index | 245 |
| Last Known Institution | Ghent University Hospital |
| OpenAlex ID | https://openalex.org/A5051854606 |
| ORCID iD | https://orcid.org/0000-0003-0647-9238 |
| Works | 695 |

## Researcher papers

- [Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial](https://scholariq.org/papers/pembrolizumab-in-patients-with-advanced-hepatocellular-carcinoma-previously/)
- [Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches](https://scholariq.org/papers/spatial-proteogenomics-reveals-distinct-and-evolutionarily-conserved-hepatic-2/)
- [Osteopontin Expression Identifies a Subset of Recruited Macrophages Distinct from Kupffer Cells in the Fatty Liver](https://scholariq.org/papers/osteopontin-expression-identifies-a-subset-of-recruited-macrophages-distinct/)
- [The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology](https://scholariq.org/papers/the-predict-study-uncovers-three-clinical-courses-of-acutely-decompensated/)
- [Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/atezolizumab-plus-bevacizumab-versus-active-surveillance-in-patients-with/)
- [Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide](https://scholariq.org/papers/epidemiology-and-effects-of-bacterial-infections-in-patients-with-cirrhosis/)
- [PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis](https://scholariq.org/papers/predict-identifies-precipitating-events-associated-with-the-clinical-course-of/)
- [Effects of Hemi-Portocaval Shunts For Inflow Modulation on the Outcome of Small-for-Size Grafts in Living Donor Liver Transplantation](https://scholariq.org/papers/effects-of-hemi-portocaval-shunts-for-inflow-modulation-on-the-outcome-of-small/)

## Researcher topics

- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)
- [Liver Disease and Transplantation](https://scholariq.org/topics/liver-disease-and-transplantation/)
- [Organ Transplantation Techniques and Outcomes](https://scholariq.org/topics/organ-transplantation-techniques-and-outcomes/)
- [Hepatitis C virus research](https://scholariq.org/topics/hepatitis-c-virus-research/)
- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)

## Researcher university

- [Ghent University Hospital](https://scholariq.org/institutions/ghent-university-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.